PURA ALERT – BUY Recommendation Issued Following Research Coverage Update With $0.25 PPS Target Confirmation

New York, NY – November 20, 2018 - Puration, Inc. (PURA) received a BUY recommendation from AmericBulls.com after the Goldman Small Cap Research yesterday released an update to its ongoing research coverage of PURA that confirmed a Speculative BUY and $0.25 PPS Target PPS.

Screen Shot 2018-11-21 at 7.21.40 AM.png

Americanbulls.com:

“Our system’s recommendation today is to BUY. The BULLISH STOP LOSS pattern finally received a confirmation because the prices crossed above the Stop Loss level which was at 0.1089, and our valid average buying price stands now at 0.1091.

A rally after a bear setup can occasionally turn into an explosive long trade. We may be on the verge of catching one of them. There is now a strong positive sentiment in the market despite the absence of a bullish pattern. The bullish stop loss is finally confirmed, and a BUY signal is generated. The Market wants to reward the bulls. It may be the right time to be part of this boost and bullish market sentiment by joining the growing bullish crowd.”

Goldman Small Cap Research:

“PURA announced very strong 3Q18 results and the best is yet to come. As a result, we believe that current prices represent a terrific entry point for opportunistic investors. Moreover, we expect PURA could return to its 52-week high of $0.25 early next year, on the heels of products with new, upgraded packaging which will begin reaching stores next week. PURA’s new package form is priced at a convenient $20 per 4-pack. Management believes that this new form will take sales to the next level.

We believe our forecasts are conservative. For 2019, we estimate sales will reach $3M, with operating profit of $800,000. It should be noted that these figures exclude any contributions from new products which are likely to be introduced in the coming weeks. Separately, an under the radar near-term catalyst is the pending dividend related to the transaction with Nouveau Life Pharmaceuticals, (OTC - NOUV). NOUV formally declared a 1:5 stock dividend whereby NOUV common will be issued to PURA shareholders at a ratio of one NOUV common share for every five shares of PURA held on the yet to be determined date of record.  Although this event is not factored into the current stock price, we believe these shares could rise ahead of the record date announcement.“

DISCLAIMER: NextBigTicker.com (NBT)is a third party publisher and news dissemination service provider. NBT is NOT affiliated in any manner with any company mentioned herein. NBT is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. NBT's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. NBT is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. NBT has not been compensated for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Source: www.nextbigticker.com